Center for Biologics Evaluation and Research

1. Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn A. Wilson, Ph.D. Associate Director for Research

2. CBER Our Vision Innovative Technology Advancing Public Health • Protect and improve public and individual health in the US and globally • Facilitate development, approval, and access to safe and effective products and promising new technologies • Strengthen CBER as a pre-eminent regulatory organization for biologics

3. CBER Our Mission To ensure the safety, purity, potency, and effectiveness of biological products, including vaccines, blood and blood products, and cells, tissues, and gene therapies for the prevention, diagnosis, and treatment of human diseases, conditions, or injury; and help to defend the public against the threats of emerging infectious diseases and bioterrorism

4. CBER Regulates Complex Products Blood, Blood Components and Derivatives Cell & Gene Therapies Vaccines: Preventive & Therapeutic Xenotransplantation Products Tissues Related Devices Allergenic Products

5. CBER Strategic Goals • Increase national preparedness to address threats from bioterrorism, pandemic and EIDs • Improve global public health through international collaboration • Enhance ability of science and technologyto facilitate development of safe and effective biological products • Ensure safety of biological products • Advance regulatory science and research • Manage for organizational excellence

6. CBER Vision for Regulatory Science and Research • Proactive, responsive, and collaborative • Provide CBER with scientific expertise, tools, and data to support science-based decision making and policy development

7. Using Science and Regulation to Advance Product Development Novel Product Regulatory Challenge Licensed Product Public Health + Improved Data – Benefit/Risk Regulatory Science Discovery New Tools Regulatory Policy/Decision

8. CBER Organization Communication, Outreach and Development Director Deputy Associates Management Compliance, Biologics Quality Biostatistics and Epidemiology Cellular, Tissue, and Gene Therapies Vaccines Research And Review Blood Research And Review

9. CBER Research Facilities • Biotechnology Core Facility • Oligonucleotide, siRNA, PNA, and peptide synthesis • Peptide and DNA sequencing • Taqman Probe synthesis • HPLC; Capillary electrophoresis • Mass Spectrometry/Proteomics • Amino acid analysis • Core support for • Flow Cytometry: Sorting/Analytic • Confocal microscopy • Vivarium with procedure rooms • Rodents, NHP, BSL-2 capacity for infectious agents • BSL-3 and ABSL-3 laboratories

10. Scientific Expertise • Novel technologies: NMR, mass spec, flow cytometry, high throughput sequencing • Microbiology: parasitology, bacteriology, virology • Immunology • Biochemistry and molecular biology • Cell and developmental biology

11. CBER researcher =“Researcher-Regulator”~20% CBER Staff Integration of research and review ensures Relevance, Expertise, Timeliness, and Usability

12. CBER RESEARCH MANAGEMENT OVERVIEW CBER RESEARCH PRIORITIES EXTERNAL REVIEW AND INPUT • IDENTIFICATION • OF • REGULATORY • AND • PUBLIC • HEALTH NEEDS OFFICE RESEARCH PLANS AND PRIORITIES RESEARCH PROGRAMS

13. CBER Research Priorities* Ensure safety, efficacy and availability of biologic products and use and development of appropriate regulatory pathways through • Development and evaluation of methods, reagents, standards • Evaluation, development, integration of novel scientific technologies and preclinical models for use in product regulation, including development and analysis of novel approaches that reduce, refine, or replace use of animals (3R’s) • Facilitation of the development of new biological products for control of high priority public health threats, including pandemic influenza, emerging infectious diseases, and agents of bioterrorism. *FY10

14. CBER Research Priorities - continued • Improving clinical trial design and evaluation, including adaptive design approaches • Enhance risk management, risk assessment, and risk communication sciences • Developing improved analytical tools and new means to access large medical databases to perform active population-based safety surveillance, including support of FDA's Sentinel Initiative.

15. Cyclic Peer Review of Every PI Every 4 Years • Internal – Promotion, Conversion, Evaluation Committee • External – peer review by scientific experts, Site Visits

16. Annual Review of Research PI provides For each project Progress report Future plans Budget Request Presentations, Pubs Other output Information reviewed Lab chief, DD, ADR, OD Relevance Productivity Quality Research Reporting Database Funding Allocated Relevance to priority Scientific/Reg Output Feasiblity

17. Site-Visit Report • Draft report is distributed to full Advisory Committee • Final report is approved by full Advisory Committee • Final report used in many ways: • Internal peer review of research/PI by Promotion, Conversion, Evaluation Committee (PCE) for personnel actions • By PIs for improving research program • By management, resource allocation decisions may be impacted by report (pending resource availability)

18. Thank you! To the Site Visit reviewers and Advisory Committee Your input improves CBER’s research programs External review is critical to fulfilling our regulatory mission!